Open Orphan (LON:ORPH) said the UK government's Covid Human Challenge Programme, in which the company’s hVIVO subsidiary is a key component, has won support from the influential New England Journal of Medicine (NEJM).
The NEJM article is titled 'Establishing the Model During an Evolving Pandemic'.
Open Orphan chairman Cathal Friel said it “articulates the considerable review process commissioned by the UK Government and delivered by hVIVO, in collaboration with the Royal Free London NHS Foundation Trust, and Imperial College London”.
“We believe the UK Government's COVID-19 Human Challenge Programme will play a vital role in trialling the vaccines and antivirals which continue to support our effective pandemic response in the UK and abroad," he added.